Encoding and Processing Patient Allergy Information in Ehrs
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Allergic Reactions After Vaccination: Translating Guidelines Into Clinical Practice
R E V I E W EUR ANN ALLERGY CLIN IMMUNOL VOL 51, N 2, 51-61, 2019 A. RADICE1, G. CARLI2, D. MACCHIA1, A. FARSI2 Allergic reactions after vaccination: translating guidelines into clinical practice 1SOS Allergologia e Immunologia, Firenze, Azienda USL Toscana Centro, Italy 2SOS Allergologia e Immunologia, Prato, Azienda USL Toscana Centro, Italy KEYWORDS Summary vaccine; vaccination; allergic reactions; Vaccination represents one of the most powerful medical interventions on global health. anaphylaxis; vaccine hesitancy; vaccine Despite being safe, sustainable, and effective against infectious and in some cases also components; desensitization non-infectious diseases, it’s nowadays facing general opinion’s hesitancy because of a false perceived risk of adverse events. Adverse reactions to vaccines are relatively rare, instead, and those recognizing a hypersensitivity mechanism are even rarer. Corresponding author The purpose of this review is to offer a practical approach to adverse events after vaccina- Anna Radice Ospedale San Giovanni di Dio tion, focusing on immune-mediated reactions with particular regard to their recognition, Via Torregalli 3, 50143 Firenze diagnosis and management. Phone: +39 055 6932304 According to clinical features, we propose an algorythm for allergologic work-up, which E-mail: [email protected] helps in confirming hypersensitivity to vaccine, nonetheless ensuring access to vaccination. Finally, a screening questionnaire is included, providing criteria for immunisation in spe- Doi cialized care settings. 10.23822/EurAnnACI.1764-1489.86 Introduction The gain from vaccination is not just about human health, but it is also a matter of financial resources for health systems. “Smallpox is dead” stated the magazine of the World Health It has been calculated that for every dollar spent in vaccines, Organisation (WHO) in 1980. -
The Rights of Children in Biomedicine: Challenges Posed by Scientific Advances and Uncertainties
The Rights of Children in Biomedicine: Challenges posed by scientific advances and uncertainties Kavot Zillén, Jameson Garland, & Santa Slokenberga Table of Contents About the Authors ...................................................................................................................... v Executive summary .................................................................................................................... 1 Resumé ....................................................................................................................................... 2 1. Introduction ............................................................................................................................ 4 1.1 The aims of the report ...................................................................................................... 4 1.2 Scientific challenges in biomedicine, pediatric care, and law .......................................... 5 1.2.1 Identifying the vulnerabilities and diversity of children as a class ........................... 5 1.2.2 Conceptualizing risk in relation to scientific advances, uncertainties, and rights ..... 6 1.2.3 Locating uncertainty and risk in biomedicine ........................................................... 7 1.3 The parameters and methodology of the report ............................................................... 8 1.4 The structure and disposition of the report ..................................................................... 10 2. Child development and its relation -
Drug Allergies: an Epidemic of Over-Diagnosis
Drug Allergies: An Epidemic of Over-diagnosis Donald D. Stevenson MD Senior Consultant Div of Allergy, Asthma and Immunology Scripps Clinic Learning objectives • Classification of drug induced adverse reactions vs hypersensitivity reactions • Patient reports of drug induced reactions grossly overstate the true prevalence • The 2 most commonly recorded drug “allergies”: NSAIDs and Penicillin • Accurate diagnoses of drug allergies • Consequences of falsely identifying a drug as causing allergic reactions Classification of Drug Associated Events • Type A: Events occur in most normal humans, given sufficient dose and duration of therapy (85-90%) – Overdose Barbiturates, morphine, cocaine, Tylenol – Side effects ASA in high enough doses induces tinnitus – Indirect effects Alteration of microbiota (antibiotics) – Drug interactions Increased blood levels digoxin (Erythromycin) • Type B: Drug reactions are restricted to a small subset of the general population (10-15%) where patients respond abnormally to pharmacologic doses of the drug – Intolerance: Gastritis sometimes bleeding from NSAIDs – Hypersensitivity: Non-immune mediated (NSAIDs, RCM) – Hypersensitivity: Immune mediated (NSAIDs, Penicillins ) Celik G, Pichler WJ, Adkinson Jr NF Drug Allergy Chap 68 Middleton’s Allergy: Principles and Practice, 7th Ed, Elsevier Inc. 2009; pg 1206 1206. Immunopathologic (Allergic) reactions to drugs (antigens): Sensitization followed by re-exposure to same drug antigen triggering reaction Type I Immediate Hypersensitivity IgE Mediated Skin testing followed -
Health Science: Biomedicine Public Service Endorsement
INNOVATE • COLLABORATE • EDUCATE • INNOVATE • COLLABORATE • EDUCATE Health Science: Biomedicine Public Service Endorsement Career Pathways • Biochemist • Biomedical Engineer • Biophysicist • Physician, Surgeon Certifications / Certificate Options • CPR • OSHA Program Highlights Biomedical engineering represents new areas of medical research and • Pathogen Analysis product development; biomedical engineers’ work helps pave the way • Human Anatomy & Physiology for new ways to help treat injuries and diseases. As medicine is a field • DNA / Genomics with vast numbers of specific disciplines, there are many different sub- • Laboratory Procedures fields in which biomedical engineers work. Some work to improve and • Dissection develop new machinery, such as robotic surgery equipment; others • Grow and Culture Bacteria endeavor to create better, more reliable replacement limbs (or parts • Real World Research which help existing limbs function better, such as joint replacements). • Learn to Treat Patients New and more comfortable patient beds, monitoring equipment, and electronics are also products that often begin as concepts from the CTSO(s) biomedical engineer’s or involve some level of input from them. • HOSA - Future Health Professionals KISD Biomedical Program: Program Fees / Requirements Biomedicine classes in KISD aim to prepare students to enter the • HOSA membership (Optional) health care field by giving them a foundation in real world problems, medical treatments, and a better understanding of the human body. Program Location Students will investigate causes and treatments of diseases that R Course(s) available at CHS affect the entire world as well as ones found in our own community. R Course(s) available at FRHS Students learn advanced techniques used in hospitals and research R Course(s) available at KHS labs and will become familiar with protocols used by doctors and R Course(s) available at TCHS researchers today. -
Biomedicine, Pharmacy and Health Care SECTORAL SERVICES of MATHEMATICAL RESEARCH Spanish Network for Mathematics & Industry for COMPANIES C/ Lope Gómez De Marzoa, S/N
Biomedicine, pharmacy and health care SECTORAL SERVICES OF MATHEMATICAL RESEARCH Spanish Network for Mathematics & Industry FOR COMPANIES C/ Lope Gómez de Marzoa, s/n. Campus Vida | CP 15782 Santiago de Compostela (A Coruña) Tel. 881 813 373 | 881 813 223 [email protected] | www.math-in.net math- in Biomedicine, Pharmacy and Health Care Specialized services Mathematics is an effective tool with proven ability to Biomedicine, Pharmacy and Health industries bring meet the demands and needs of businesses. In Spain, together the supply of 29 research groups of the i-MATH Biomedicine and Pharmacy many innovative solutions emerged from the experience project, of which up to 20 have proven experience from gained by research groups in this field through successful having effectively carried out consulting activities, training • Analysis and design of experiments. • Studies of efficacy and safety of treatments. partnerships with industry over the years. All those courses and other collaborations. The details of these • Characterization/grading of pharmaceutical and medical waste. encouraging cases support its potential in offering an groups can be found in the 'Sectors' section of the • Modelling of mortality tables. increasingly sophisticated and complete service to the platform www.math-in.net. • Numerical simulation of fractures, dental implants and orthodontic brackets. industry. • Biomechanics. Bones formation. The mathematical technology services provided in this • Bioinformatics. • Mathematical Biology. Synthetic Biology. The Spanish Network for Mathematics & Industry sector can be broken down into two blocks (on the one • Computational design of proteins. (math-in) is a stable platform that continues the work hand, Biomedicine and Pharmacy and, on the other • Metabolism. -
Biomedicine and Health Innovation
Biomedicine and Health Innovation SYNTHESIS REPORT • Industrial Biotechnology • Green Growth • Bio-based Products • Measuring Performance OECD Innovation Strategy June 2010 Biomedicine and Health Innovation Synthesis Report November 2010 2 BIOMEDICINE AND HEALTH INNOVATION: SYNTHESIS REPORT Table of contents BIOMEDICINE AND HEALTH INNOVATION: SYNTHESIS REPORT ........................ 3 I. Introduction ................................................................................................................. 3 II. The changing nature of health innovation ............................................................. 4 III. Lessons and policy recommendations ................................................................... 7 IV. New policy challenges from advances in biomedicine ...................................... 14 Annex. Summary of OECD reports on biomedicine and health innovation ........ 19 OECD 2010 BIOMEDICINE AND HEALTH INNOVATION: SYNTHESIS REPORT 3 BIOMEDICINE AND HEALTH INNOVATION SYNTHESIS REPORT I. Introduction Over the past few years, the OECD has done important work in a number of areas related to innovation in biomedicine, including on: genetics and genomics, intellectual property rights and collaborative mechanisms and knowledge markets, health research infrastructures, translational research, regulatory policies that affect the approval and uptake of new technologies, and new business models for bringing health products to market, etc. This synthesis report presents the main lessons and policy messages that emerge -
Prevalence and Impact of Reported Drug Allergies Among Rheumatology Patients
diagnostics Article Prevalence and Impact of Reported Drug Allergies among Rheumatology Patients Shirley Chiu Wai Chan , Winnie Wan Yin Yeung, Jane Chi Yan Wong, Ernest Sing Hong Chui, Matthew Shing Him Lee, Ho Yin Chung, Tommy Tsang Cheung, Chak Sing Lau and Philip Hei Li * Division of Rheumatology and Clinical Immunology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong; [email protected] (S.C.W.C.); [email protected] (W.W.Y.Y.); [email protected] (J.C.Y.W.); [email protected] (E.S.H.C.); [email protected] (M.S.H.L.); [email protected] (H.Y.C.); [email protected] (T.T.C.); [email protected] (C.S.L.) * Correspondence: [email protected]; Tel.: +852-2255-3348 Received: 28 October 2020; Accepted: 7 November 2020; Published: 9 November 2020 Abstract: Background: Drug allergies (DA) are immunologically mediated adverse drug reactions and their manifestations depend on a variety of drug- and patient-specific factors. The dysregulated immune system underpinning rheumatological diseases may also lead to an increase in hypersensitivity reactions, including DA. The higher prevalence of reported DA, especially anti-microbials, also restricts the medication repertoire for these already immunocompromised patients. However, few studies have examined the prevalence and impact of reported DA in this group of patients. Methods: Patients with a diagnosis of rheumatoid arthritis (RA), spondyloarthritis (SpA), or systemic lupus erythematosus (SLE) were recruited from the rheumatology clinics in a tertiary referral hospital between 2018 and 2019. Prevalence and clinical outcomes of reported DA among different rheumatological diseases were calculated and compared to a cohort of hospitalized non-rheumatology patients within the same period. -
Reflections on Humanizing Biomedicine
07_51.3marcum 392–405:02_51.3schwartz 320– 6/25/08 1:34 PM Page 392 Reflections on Humanizing Biomedicine James A. Marcum ABSTRACT Although biomedicine is responsible for the “miracles” of modern medicine, paradoxically it has also led to a quality-of-care crisis in which many patients feel disenfranchised from the health-care industry. To address this crisis, several medical commentators make an appeal for humanizing biomedicine, which has led to shifts in the philosophical boundaries of medical knowledge and practice. In this paper, the metaphysical, epistemological, and ethical boundaries of biomedicine and its human - ized versions are investigated and compared to one another. Biomedicine is founded on a metaphysical position of mechanistic monism, an epistemology of objective knowing, and an ethic of emotionally detached concern. In humanizing modern medicine, these boundaries are often shifted to a metaphysical position of dualism/holism, an episte - mology of subject knowing, and an ethic of empathic care. In a concluding section, the question is discussed whether these shifts in the philosophical boundaries are adequate to resolve the quality-of-care crisis. NAMOVING STORY OF a consultation for a second opinion over a diagnosis of I amyotrophic lateral sclerosis, Mary O’Flaherty Horn (1999), the patient (and a practicing internist), relates the inhumanity and degradation with which she was treated by health-care providers. For example, during a procedure for test - ing the motor nerves “Dr. L”—the physician conducting the test—addressed his comments to attending residents instead of to her. “I might not have been pres - Department of Philosophy, Baylor University, One Bear Place #97273, Waco, TX 76798. -
Unlocking the Non-Ige-Mediated Pseudo-Allergic Reaction Puzzle with Mas-Related G-Protein Coupled Receptor Member X2 (MRGPRX2)
cells Review Unlocking the Non-IgE-Mediated Pseudo-Allergic Reaction Puzzle with Mas-Related G-Protein Coupled Receptor Member X2 (MRGPRX2) Mukesh Kumar, Karthi Duraisamy and Billy-Kwok-Chong Chow * School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Hong Kong, China; [email protected] (M.K.); [email protected] (K.D.) * Correspondence: [email protected]; Tel.: +852-2299-0850; Fax: +852-2559-9114 Abstract: Mas-related G-protein coupled receptor member X2 (MRGPRX2) is a class A GPCR ex- pressed on mast cells. Mast cells are granulated tissue-resident cells known for host cell response, allergic response, and vascular homeostasis. Immunoglobulin E receptor (Fc"RI)-mediated mast cell activation is a well-studied and recognized mechanism of allergy and hypersensitivity reac- tions. However, non-IgE-mediated mast cell activation is less explored and is not well recognized. After decades of uncertainty, MRGPRX2 was discovered as the receptor responsible for non-IgE- mediated mast cells activation. The puzzle of non-IgE-mediated pseudo-allergic reaction is unlocked by MRGPRX2, evidenced by a plethora of reported endogenous and exogenous MRGPRX2 ag- onists. MRGPRX2 is exclusively expressed on mast cells and exhibits varying affinity for many molecules such as antimicrobial host defense peptides, neuropeptides, and even US Food and Drug Administration-approved drugs. The discovery of MRGPRX2 has changed our understanding of mast cell biology and filled the missing link of the underlying mechanism of drug-induced MC degranulation and pseudo-allergic reactions. These non-canonical characteristics render MRGPRX2 Citation: Kumar, M.; Duraisamy, K.; Chow, B.-K.-C. -
About Drug Side-Effects and Allergies
About drug side-effects and allergies Introduction This leaflet has been produced to provide you with information about side-effects of medicines and drug allergies, and the differences between the two. There are a variety of ways in which people can experience adverse reactions to medications, whether prescribed or bought 'over-the-counter'. Most of these effects are not an 'allergy'. Contrary to what most people think, only small amounts (5-10%) of all adverse drug reactions are caused by a drug allergy. It is important to tell the doctor or healthcare professional looking after you about any drug allergies or side-effects to drugs you may have/or had as this may affect your current treatment. It is important to know the difference between a drug allergy and side-effect because saying you have a drug allergy when in fact it is a side-effect may unnecessarily restrict the treatment choices available to treat your condition. What should I be aware of when taking my medicines? Many medicines can cause side-effects e.g. some medicines may affect your sight or co-ordination or make you sleepy, which may affect your ability to drive, perform skilled tasks safely. The information leaflet provided with your medicine will list any side effects which are known to be linked to your medicine. All medications have side-effects because of the way they work. The majority of people get none, or very few, but some people are more prone to them. The most common side-effects are usually nausea, vomiting, diarrhoea (or occasionally constipation), tiredness, rashes, itching, headaches and blurred vision. -
Drug Allergy: the Facts
Drug Allergy: The Facts What is drug allergy? There is more than one type of drug allergy, but this Factsheet focuses primarily on those rapidly- occurring allergic reactions that cause urticaria (also known as hives or nettle rash), angioedema (swelling) or anaphylaxis (a severe, life-threatening reaction). These reactions can occur within minutes of the drug being administered or sometimes after a few hours. This type of drug allergy happens when the person’s immune system reacts inappropriately to a particular drug, creating antibodies known as IgE. Doctors refer to this kind of allergy as “IgE mediated”. Many people experience delayed allergic reactions that do not involve IgE antibodies. Symptoms usually begin more than 24 hours after the medication is taken, but can start as early as two to six hours. The aim of this Factsheet is to provide information on those rapidly-occurring reactions involving IgE antibodies, rather than the delayed form of reactions. Our intention is to answer questions that you and your family may have about living with a drug allergy. We hope this information will help you to reduce risks to a minimum and take action should a reaction occur. Any symptoms believed to have been caused by a reaction to a drug should be taken seriously and medical advice should be sought from your GP. Referral to a specialist in managing drug allergy may be required so that the problem can be thoroughly investigated, and a proper diagnosis made. Throughout this Factsheet you will see brief medical references given in brackets. More complete references are published towards the end. -
Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs
Specific Drugs Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs Chief Editors: Ana Dioun Broyles, MD, Aleena Banerji, MD, and Mariana Castells, MD, PhD Ana Dioun Broyles, MDa, Aleena Banerji, MDb, Sara Barmettler, MDc, Catherine M. Biggs, MDd, Kimberly Blumenthal, MDe, Patrick J. Brennan, MD, PhDf, Rebecca G. Breslow, MDg, Knut Brockow, MDh, Kathleen M. Buchheit, MDi, Katherine N. Cahill, MDj, Josefina Cernadas, MD, iPhDk, Anca Mirela Chiriac, MDl, Elena Crestani, MD, MSm, Pascal Demoly, MD, PhDn, Pascale Dewachter, MD, PhDo, Meredith Dilley, MDp, Jocelyn R. Farmer, MD, PhDq, Dinah Foer, MDr, Ari J. Fried, MDs, Sarah L. Garon, MDt, Matthew P. Giannetti, MDu, David L. Hepner, MD, MPHv, David I. Hong, MDw, Joyce T. Hsu, MDx, Parul H. Kothari, MDy, Timothy Kyin, MDz, Timothy Lax, MDaa, Min Jung Lee, MDbb, Kathleen Lee-Sarwar, MD, MScc, Anne Liu, MDdd, Stephanie Logsdon, MDee, Margee Louisias, MD, MPHff, Andrew MacGinnitie, MD, PhDgg, Michelle Maciag, MDhh, Samantha Minnicozzi, MDii, Allison E. Norton, MDjj, Iris M. Otani, MDkk, Miguel Park, MDll, Sarita Patil, MDmm, Elizabeth J. Phillips, MDnn, Matthieu Picard, MDoo, Craig D. Platt, MD, PhDpp, Rima Rachid, MDqq, Tito Rodriguez, MDrr, Antonino Romano, MDss, Cosby A. Stone, Jr., MD, MPHtt, Maria Jose Torres, MD, PhDuu, Miriam Verdú,MDvv, Alberta L. Wang, MDww, Paige Wickner, MDxx, Anna R. Wolfson, MDyy, Johnson T. Wong, MDzz, Christina Yee, MD, PhDaaa, Joseph Zhou, MD, PhDbbb, and Mariana Castells, MD, PhDccc Boston, Mass; Vancouver and Montreal,